ArticleFrontiers in global women's health2026
Temporal trends in prevalence of chronic liver disease among women of childbearing age from 1992 to 2021.
Article in Frontiers in global women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic liver disease (CLD) is a leading cause of global mortality. This study aimed to comprehensively analyze the temporal trends in CLD prevalence among women of childbearing age (WCBA) over a 30-year period. Methods: An age-period-cohort (APC) model was developed to assess the overall annual percentage change [net drift (ND), % per year] and the annual percentage change within distinct age groups (local drift, % per year) in CLD prevalence from 1992 to 2021. The APC model incorporated longitudinal age-specific rates, adjusting for deviations across time periods (age effects), as well as period/cohort relative risks (period/cohort effects). Results: From 1992 to 2021, the global ND in CLD prevalence among WCBA was 0.057% per year [95% confidence interval (CI): 0.029%-0.084%], with regional variation ranging from -0.27% to 0.66%. Local drift analysis indicated that age groups with increasing prevalence were more prominent in high sociodemographic index region (SDIR), while those with decreasing prevalence were more common in low SDIR. Age effects showed consistent patterns across SDIRs, with risk increasing progressively with age. Period risks were relatively lower in low SDIR, while more adverse period risks were observed in other regions. Additionally, improvements in prevalence were seen across birth cohorts in all regions. Conclusion: Over the past three decades, the global prevalence of CLD among WCBA has predominantly exhibited an adverse trend. Targeted advancements in prevention, management, and treatment of CLD are essential to mitigate relative risks for successive birth cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.